EP3784231A4 - METHOD OF TREATMENT OF HIGH BLOOD PRESSURE - Google Patents

METHOD OF TREATMENT OF HIGH BLOOD PRESSURE Download PDF

Info

Publication number
EP3784231A4
EP3784231A4 EP19793915.0A EP19793915A EP3784231A4 EP 3784231 A4 EP3784231 A4 EP 3784231A4 EP 19793915 A EP19793915 A EP 19793915A EP 3784231 A4 EP3784231 A4 EP 3784231A4
Authority
EP
European Patent Office
Prior art keywords
treatment
blood pressure
high blood
pressure
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19793915.0A
Other languages
German (de)
French (fr)
Other versions
EP3784231A1 (en
Inventor
Jordan Mechanic
Brian Seed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theracos Sub LLC
Original Assignee
Theracos Sub LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theracos Sub LLC filed Critical Theracos Sub LLC
Publication of EP3784231A1 publication Critical patent/EP3784231A1/en
Publication of EP3784231A4 publication Critical patent/EP3784231A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19793915.0A 2018-04-25 2019-04-24 METHOD OF TREATMENT OF HIGH BLOOD PRESSURE Withdrawn EP3784231A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662526P 2018-04-25 2018-04-25
PCT/US2019/028990 WO2019209998A1 (en) 2018-04-25 2019-04-24 Methods of treating hypertension

Publications (2)

Publication Number Publication Date
EP3784231A1 EP3784231A1 (en) 2021-03-03
EP3784231A4 true EP3784231A4 (en) 2022-05-11

Family

ID=68295754

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19793915.0A Withdrawn EP3784231A4 (en) 2018-04-25 2019-04-24 METHOD OF TREATMENT OF HIGH BLOOD PRESSURE

Country Status (4)

Country Link
US (1) US20190343853A1 (en)
EP (1) EP3784231A4 (en)
TW (1) TW202038937A (en)
WO (1) WO2019209998A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613719A (en) 2019-03-14 2021-11-05 印可瑞维特有限公司 Compounds for the control of feline diabetes
WO2021092341A1 (en) * 2019-11-07 2021-05-14 Increvet, Inc. Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals
WO2022073151A1 (en) 2020-10-05 2022-04-14 Theracos Sub, Llc Pharmaceutical formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2013152476A1 (en) * 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIASOULIS ALEXANDROS ET AL: "SGLT2 Inhibitors and Mechanisms of Hypertension", CURRENT CARDIOLOGY REPORTS, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 20, no. 1, 19 January 2018 (2018-01-19), pages 1 - 7, XP036409991, ISSN: 1523-3782, [retrieved on 20180119], DOI: 10.1007/S11886-018-0943-5 *
See also references of WO2019209998A1 *
WEBER: "Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study", THE LANCET DIABETES, 1 March 2016 (2016-03-01), pages 211 - 220, XP055905037, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/S2213-8587(15)00417-9> DOI: 10.1016/S2213-8587(15)00417-9 *
WENBIN ZHANG ET AL: "EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbAlevels in db/db mice and prolongs the survival of stroke-prone rats", PHARMACOLOGICAL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 63, no. 4, 2 January 2011 (2011-01-02), pages 284 - 293, XP028141921, ISSN: 1043-6618, [retrieved on 20110105], DOI: 10.1016/J.PHRS.2011.01.001 *

Also Published As

Publication number Publication date
EP3784231A1 (en) 2021-03-03
US20190343853A1 (en) 2019-11-14
TW202038937A (en) 2020-11-01
WO2019209998A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
EP3931564A4 (en) METHODS OF TREATMENT OF MAP3K8 POSITIVE TUMORS
EP3606962A4 (en) METHOD OF TREATMENT OF CD73HI TUMORS
EP3684377A4 (en) METHOD OF TREATMENT OF HEPATITIS B INFECTIONS
EP3883580A4 (en) METHODS OF TREATMENT OF CANCER
EP3666304C0 (en) SYSTEMS AND METHODS FOR TREATMENT OF BLOOD
EP3596111A4 (en) METHOD OF TREATMENT OF LYSOSOMAL STORAGE DISEASES
EP3585778A4 (en) METHOD OF TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNOMAS
EP3566055A4 (en) METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
EP3592139A4 (en) SYSTEM AND METHOD OF TREATMENT OF FISH
EP3893883A4 (en) METHODS OF TREATMENT OF DEPRESSION
EP3565540A4 (en) METHODS FOR TREATMENT OF CARDIAC DISEASES
EP3941921A4 (en) THERAPEUTIC METHODS OF TREATMENT OF HEPATITIS B
EP3781167A4 (en) METHOD OF TREATMENT OF HEAVY MENSTRUAL BLEEDING
EP3568488A4 (en) METHOD OF TREATMENT OF HYPERTENSION AND ARTERIAL STIFFNESS
EP3886844A4 (en) METHODS OF TREATMENT OF DISEASES WITH MAGL INHIBITORS
EP3829651A4 (en) METHOD OF IDENTIFYING PATIENTS LIKELY TO BENEFIT FROM TREATMENT WITH AN INHIBITOR TELOMERA
EP3658153A4 (en) METHOD OF TREATMENT OF TUMOR METASTASIS
EP3565551A4 (en) METHOD FOR TREATMENT OF BACTERIAL INFECTION
EP3784231A4 (en) METHOD OF TREATMENT OF HIGH BLOOD PRESSURE
EP3790587A4 (en) METHOD OF TREATMENT OF DEPRESSION USING IL-23 ANTIBODIES
EP3601539A4 (en) METHOD OF TREATMENT OF NEOPLASTIC DISEASES
EP4025218A4 (en) METHOD OF TREATMENT
EP3655418A4 (en) METHOD OF TREATMENT OF GLIOBLASTOMA
EP4055062C0 (en) METHOD FOR THE TREATMENT OF ALGAE
EP3924060A4 (en) METHOD OF TREATMENT OF SKIN AGING

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220411

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101ALI20220405BHEP

Ipc: A61K 31/715 20060101ALI20220405BHEP

Ipc: A61K 31/7012 20060101ALI20220405BHEP

Ipc: A61K 31/4025 20060101AFI20220405BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221101